| Alemtuzumab |
Campath (Genzyme) |
CD52 |
Humanized |
Chronic lymphocytic leukemia |
| Bevacizumab |
Avastin (Roche) |
VEGFA |
Humanized |
CRC, NSCLC, RCC, glioblastoma |
| Cetuximab |
Erbitux (Bristol-Myers Squibb/Lilly) |
EGFR |
Chimeric |
CRC, breast, lung |
| Denosumab |
Xgeva/Prolia (Amgen) |
RANK ligand |
Human |
Solid tumor bony metastases |
| Gemtuzumab ozogamicin |
Mylotarg (Wyeth) |
CD33 |
Humanized |
Acute myeloid leukemia |
| Nimotuzumab |
Theraloc/TheraCIM (YM Biosciences) |
EGFR |
Humanized |
Head and neck |
| Ofatumumab |
Arzerra (GlaxoSmithKline) |
CD20 |
Human |
Chronic lymphocytic leukemia |
| Panitumumab |
Vectibix (Amgen) |
EGFR |
Human |
CRC |
| Pertuzumab |
Perjeta (Roche) |
HER2 |
Humanized |
Breast |
| Rituximab |
Rituxan/MabThera (Biogen, Roche) |
CD20 |
Chimeric |
Non-Hodgkin’s lymphoma |
| Tositumomab and 131I-tositumomab |
Bexxar (GlaxoSmithKline) |
CD20 |
Mouse |
Lymphoma |
| Trastuzumab |
Herceptin (Roche) |
HER2 |
Humanized |
Breast |
